Themed “Charting a New Course in Healthcare through Collaboration, the second Asia Summit on Global Health will be staged in Hong Kong on 10-11 November.
Convergence of top-notch talents, investment capital and inherently advantageous geographical location leveraging on the Mainland China while engaging the world, makes Hong Kong Asia’s top biotech fundraising hub.
[The content of this article has been produced by our advertising partner.]
Blooming prospect of healthcare: bridging industry development and investment opportunities
The pandemic has accelerated businesses to explore the lucrative business opportunities in the healthcare and medical sector. The Hong Kong Trade Development Council (HKTDC) has been providing resourceful platforms to facilitate business connections, ranging from research and innovation on the upstream, to manufacturing of equipment and devices on the downstream.
The inaugural “International Healthcare Week” (IHW) will be coordinated by HKTDC to bring together close to ten healthcare-related events in Hong Kong, creating synergy in global partnership of healthcare leveraging Hong Kong’s role as an innovation and investment hub during the period from 1-15 November, including Asia Summit on Global Health (ASGH). It will provide a platform for investment community to connect with global opportunities.
Haitong International, Hong Kong-based investment bank of leading China brokerage, eyes on healthcare industry. It completed over 30 healthcare companies initial public offerings in the past 5 years including China's largest clinical research service firm Hangzhou Tigermed Consulting (as of its listing in 2020).
Citing Hong Kong as an international financial hub with strong medical talents, executive committee member of Haitong International Henry Shi firmly believes in the city's unique advantage for her “openness, transparency and regulation which is widely accepted by the world”. He affirms it will continuously attract Asia including China’s biotech firms to list in Hong Kong, especially after HKEX Chapter 18A reform enabling pre-revenue biotech firms to list.
“China healthcare security system reform breeds immense investment opportunities,” Shi said. He sees a promising future in areas such as novel drug discovery, AI-based platform for medicines development, and medical devices like high-end medical imaging systems.
